Search

Search Constraints

Start Over Filtering by: Keyword LENALIDOMIDE Remove constraint Keyword: LENALIDOMIDE

Search Results

  • Efficacy, safety, and cost of mobilization strategies in multiple myeloma: a prospective, observational study
  • Peri-CAR-T practice patterns and survival predictors for all CAR-T patients and post-CAR-T failure in aggressive B-NHL
  • Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial
  • Postibrutinib relapse outcomes for patients with marginal zone lymphoma
  • Phase I Study of Venetoclax Plus Daratumumab and Dexamethasone, With or Without Bortezomib, in Patients With Relapsed or Refractory Multiple Myeloma With and Without t(11;14)
  • Keeping Myeloma in Check: The Past, Present and Future of Immunotherapy in Multiple Myeloma
  • Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins
  • Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
  • Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO)
  • Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial